At present, blockade of inhibitory molecules such as the PD‐1/PD‐L1 is the most widely used in immunotherapy, but unfortunately, the OC response to PD‐L1/PD‐1 blockade is weaker than that of other tumour types. This evidence concerns the gene PDCD1 and neoplasm.